Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 5Neoplasm Metastasis 4Lung Neoplasms 4Adenocarcinoma 3Stomach Neoplasms 2Pancreatic Diseases 2Neoplasms by Site 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Carcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Pericardial Effusion 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Non-Small-Cell Lung 1Non Small Cell Lung Cancer NSCLC 1Neuralgia 1Neoplasms, Unknown Primary 1

Interventions

osimertinib 3Vinorelbine 3Pemetrexed 3Cisplatin 3Carboplatin 3Gemcitabine 2Gefitinib 2Docetaxel 2CP protocol 2rezivertinib 1pembrolizumab 1aumolertinib 1Taxes 1Paclitaxel 1HMPL-013 1HM781-36B 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NSCLC × Albumin-Bound Paclitaxel × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡